Skip to main content
Premium Trial:

Request an Annual Quote

Don Van Dyke, Stan Yakatan, Axel Ullrich

Premium

Don Van Dyke has been hired as vice president of business development at Incogen. Van Dyke most recently served as a consultant to Incogen. Prior to that, he was vice president of sales and marketing at Molecular Mining and president and CEO of Bio Image.


Phenomenome Discoveries of Saskatoon, Saskatchewan, Canada, has appointed Stan Yakatan to its board of directors. Yakatan is president of Katan Associates, and has 30 years’ experience as an entrepreneur. He has founded or co-founded more than 15 companies, and served as an executive at New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific, and Biosearch. Phenomenome Discoveries uses a proprietary metabolite analysis and bioinformatics platform to study biological samples.


The Singapore Onco Genome Laboratory has tapped Axel Ullrich from the Max Planck Institute of Biochemistry in Martinsried, Germany, to lead its research team. The laboratory is a joint research program between the Max Planck Society and Singapore’s Agency for Science, Technology and Research. Ullrich will lead an effort at the center to guild a gene database of cancer cell lines and tumor tissues using a new gene identification signature technology developed by the Genome Institute of Singapore.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.